An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD).

Trial Profile

An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD).

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 23 May 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Aug 2016.
    • 17 May 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2016.
    • 17 May 2017 Status changed from recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top